Full Title
Phase II Study of Reparixin in Patients with Myelofibrosis (MPN-RC 120) (BRANY IRB)Purpose
Researchers want to see how well reparixin works against myelofibrosis. This disease is a rare bone marrow cancer that disrupts your body’s normal blood cell production.
Reparixin may help treat myelofibrosis by blocking inflammatory signals of interleukin-8 (IL-8) by inhibiting the receptors CXCR1 and CXCR2. It is taken orally (by mouth).
Contact
For more information or to see if you can join this study, please call Dr. Brian Chernak’s office at 646-608-4366.
Protocol
25-253
Phase
Phase II (phase 2)
Investigator
Co-Investigators
Locations
ClinicalTrials.gov ID
NCT05835466
ClinicalTrials.gov